Research programme: stem cell modulators - Fate Therapeutics

Drug Profile

Research programme: stem cell modulators - Fate Therapeutics

Alternative Names: FT 4145

Latest Information Update: 21 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator The Scripps Research Institute
  • Developer Fate Therapeutics
  • Class Biological proteins; Small molecules; Wnt proteins
  • Mechanism of Action Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Musculoskeletal disorders; Neurological disorders
  • Research Heart failure

Most Recent Events

  • 02 Nov 2015 Fate Therapeutics in-licenses intellectual properties from The Scripps Research Institute (Fate Therapeutics 10-K, filed in March 2015)
  • 02 Nov 2015 Fate Therapeutics has patent protection for stem cell modulators in USA
  • 29 May 2013 Preclinical trials in Musculoskeletal disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top